THYROID THERAPEUTIC AGENT

摘要

The invention relates to oral therapeutic agents containing at least one active ingredient and, as adjuvants, dextrins and higher-chain partial glycerides as well as additional pharmaceutically acceptable adjuvants and excipients. The invention makes it possible to forgo cost-intensive bioavailability and bioequivalence tests for all (conceivable) dosage strengths located within the established linearity range, in particular, to realize a dosage scheme individually adapted to the patient, and to reduce the, until now, customary regular medical check-ups of patients with an L-thyroxine medication.